New hope for tough brain tumors: experimental drug SYHA1813 faces off against standard care
Disease control
Not yet recruiting
This Phase 3 trial tests a new drug called SYHA1813 against standard treatments (bevacizumab, temozolomide, or hydroxyurea) in 136 adults with recurrent or progressive high-grade meningioma. Participants must have already had surgery and radiation. The main goal is to see if SYHA…
Phase: PHASE3 • Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC